Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Receivables (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Change in Receivables for 11 consecutive years, with $393000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 109.93% to $393000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $243000.0, a 104.86% increase, with the full-year FY2025 number at $243000.0, up 104.86% from a year prior.
  • Change in Receivables was $393000.0 for Q4 2025 at Cartesian Therapeutics, up from $368000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $30.0 million in Q2 2024 to a low of -$27.2 million in Q3 2024.
  • A 5-year average of -$305450.0 and a median of -$103000.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 13591.87% in 2022, then tumbled 5487.27% in 2024.
  • Cartesian Therapeutics' Change in Receivables stood at $2.6 million in 2021, then crashed by 112.7% to -$329000.0 in 2022, then surged by 395.44% to $972000.0 in 2023, then crashed by 507.1% to -$4.0 million in 2024, then surged by 109.93% to $393000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Change in Receivables are $393000.0 (Q4 2025), $368000.0 (Q3 2025), and -$1.4 million (Q2 2025).